Developer docs
API playgroundTry for free, no card

Search company profiles

adMare Bio Innovations

Full company profile

uuid0000qvt

Namestring
adMare Bio Innovations
Legal namestring
adMare BioInnovations
Websiteurl
admarebio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

adMare BioInnovations is a Canadian life sciences company creation engine formed in 2019 from the merger of CDRD (Centre for Drug Research and Development) and Neomed Institute. The organization is structured as a mission-driven, non-profit platform that provides early-stage capital, scientific and commercial drug development expertise, intellectual property support, and turnkey laboratory and office infrastructure to help build and scale globally competitive Canadian life sciences companies. It serves three primary constituencies: early-stage life sciences companies (its core customer), life sciences professionals across Canada (community), and mid-career executives (leadership development). The organization operates over 200,000 square feet of turnkey facilities across three locations: the Vancouver Innovation Centre (including the newly opened M4 Centre in April 2026), the Montreal Innovation Centre, and a Toronto office at the MaRS Centre. The business model is not traditional commercial revenue generation; adMare is funded through government grants, service and facility income, and reinvested returns from portfolio company exits. Its product and service platform spans three pillars: Company Building (pre-seed investment, scientific and commercial R&D, IP and business development support), Ecosystems (innovation centre facilities, the AbbVie Biotech Innovators Award, and the adMare Community digital platform hosted on Hivebrite with 2,000+ members), and Talent (the adMare Executive Institute, adMare Academy's BIS Program, and experiential learning). The adMare Institute operates as a policy research arm producing white papers on Canadian life sciences.

adMare has helped create 39 companies that have collectively attracted $2.5 billion in risk capital and achieved a combined value of $5.8 billion, while generating more than $130 million in cash returns that are reinvested into the Canadian ecosystem. Recent portfolio company activity includes the launch of 26therapeutics (March 2026, dry eye disease), seed funding of Ocythera (January 2026, rare bone disease), Series B participation in Kainova Thérapeutiques ($32M CAD, February 2026, immuno-oncology), and the naming of RIME Therapeutics as the April 2026 AbbVie Biotech Innovators Award recipient. The adMare Academy has trained 800+ alumni (91% employed in the life sciences industry) and the Executive Institute has developed nearly 150 executives from over 100 Canadian life sciences organizations. Federal government support has been a material funding source, with grants from Innovation, Science and Economic Development Canada ($5M, December 2023) and Pacific Economic Development Canada ($4.2M, February 2025). In March-April 2026, founding President and CEO Gordon McCauley transitioned to Vice-Chair, with nine-year adMare executive Matthew J. Carlyle appointed President, CEO, and Director; Frédéric Lemaître Auger was concurrently promoted to Executive Vice President, Investments.

Short descriptiontext

adMare BioInnovations is a Canadian mission-driven life sciences platform that provides early-stage capital, scientific and commercial expertise, turnkey lab facilities, and talent development to build and scale Canadian biotech companies. To date, it has helped create 39 companies with $5.8 billion in combined value.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotech company creation, life sciences venture building, pharmaceutical R&D infrastructure, biotech talent development, drug development services
Industry3 codes
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Life Sciences Company Creation & Biotech Venture Development
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Portfolio Returns and Reinvestment
TypeLicensing Royalties
Description

adMare generates returns through its portfolio company exits (IPOs, M&A) and reinvests those returns back into the Canadian life sciences industry. The organization has generated more than $130 million in cash returns, which are plowed back into building new companies and supporting the ecosystem.

admarebio.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1adMare Executive Institute
Description

Canada's premier leadership development program for experienced mid-career executives and emerging C-suite leaders in the life sciences sector.

admarebio.com
+5 more records
Core offering1 text field

adMare BioInnovations is a Canadian life sciences company creation engine that identifies breakthrough scientific discoveries and builds globally competitive biotech companies. It provides early-stage capital, scientific and commercial drug development expertise, turnkey laboratory and office infrastructure at Innovation Centres in Vancouver, Montreal, and Toronto, and industry-ready talent development programs, reinvesting returns from portfolio exits back into the Canadian life sciences ecosystem.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 39 companies created that have attracted $2.5 billion in risk capital and achieved $5.8 billion combined value
+4 more records
Product overview1 text field

adMare BioInnovations is Canada's life sciences company creation engine, offering a multi-component platform built around three pillars: (1) Company Building — providing early-stage capital, scientific expertise, commercial R&D, IP and business development support to create and scale globally competitive life sciences companies; (2) Ecosystems — operating turnkey lab and office facilities through Innovation Centres in Vancouver, Montreal, and Toronto (totaling more than 200,000 square feet), running the AbbVie Biotech Innovators Award competition, and maintaining the adMare Community digital networking platform; and (3) Talent — delivering the adMare Executive Institute (leadership development), BIS Program, and Experiential Learning programs. The adMare Institute provides policy research and white papers. adMare's portfolio includes 39 companies created to date, with a combined value of $5.8 billion.

Product and service10 records
1adMare Innovation Centre – Vancouver
CategoryFacility & Infrastructure Services
Description

Turnkey laboratory and office facilities at 2405 Wesbrook Mall, Vancouver, British Columbia, providing workspace for emerging life sciences companies.

2adMare Innovation Centre – Montreal
CategoryFacility & Infrastructure Services
Description

Turnkey laboratory and office facilities at 7171 Frederick-Banting, Montréal, Québec, offering shared equipment and services for early-stage biotech companies.

3adMare Executive Institute
CategoryExecutive Leadership Program
Description

Canada's premier leadership development program for experienced mid-career executives and emerging C-suite leaders in the life sciences sector, combining in-person workshops, virtual peer sessions, executive coaching, and real-world leadership challenges. Has trained nearly 150 participants from more than 100 organizations across Canada.

4AbbVie Biotech Innovators Award
CategoryAward Program
Description

A national competition jointly run by AbbVie and adMare providing the winning Quebec biotech with one year of free laboratory and office space at the adMare Innovation Centre in Montreal, shared equipment access, and mentorship from AbbVie's scientific and business leaders.

5adMare Accelerator
CategoryAccelerator Program
Description

An accelerator program for early-stage life sciences ventures providing hands-on company building support, capital, and access to infrastructure.

6adMare Academy (BIS Program and Experiential Learning)
CategoryEducation & Training Program
Description

Industry-ready talent development programs including the Business Innovation Studies (BIS) Program and experiential learning offerings that prepare individuals for careers in the Canadian life sciences industry. The Academy has trained more than 800 alumni, with 91% employed in the life sciences industry.

7adMare Community
CategoryDigital Networking Platform
Description

A digital ecosystem bringing together over 2,000 life sciences professionals from students to CEOs across Canada, hosted on the Hivebrite platform, enabling networking, collaboration, and knowledge sharing.

8Early-Stage Capital & Company Creation
CategoryVenture Investment & Company Building
Description

Pre-seed and early-stage investment capital provided to life sciences companies, with adMare co-investing alongside other investors to build globally competitive Canadian companies. To date, adMare has helped create 39 companies that have attracted $2.5 billion in risk capital.

9adMare Institute
CategoryPolicy Research Institute
Description

A policy research institute dedicated to advancing public policy issues in life sciences in Canada, producing white papers on capital flows, anchor companies, and ecosystem development.

1026therapeutics Inc.
CategoryPortfolio Company (Therapeutics)
Description

Montreal-based life sciences company developing first-in-class topical small-molecule therapy for dry eye disease targeting meibomian gland dysfunction through CYP26B1 inhibition, created via adMare's company creation model.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

Research partnership to validate the scientific and commercial potential of a novel antibody-based immune-modulating therapy using VoxCell's human-relevant vascularized cancer tissue models. Collaboration applies perfusable, immune-competent 3D bioprinted cancer tissue models to preclinical evaluation of next-generation oncology biologics.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-17
Description

Partnership with Life Sciences BC for ecosystem development. Life Sciences BC executives attended the ribbon-cutting ceremony for new lab facilities at adMare's Vancouver innovation centre.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-11-24
Description

AbbVie and adMare jointly run the AbbVie Biotech Innovators Award program to support early-stage biotechnology companies in Quebec. The award provides lab/office space at the adMare Innovation Centre in Montreal, shared equipment access, and mentorship from AbbVie's scientific and business leaders. First awarded to RIME Therapeutics in April 2026.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

JLABS operates a global network of no-strings-attached biotech incubators offering turnkey lab space, equipment, and mentorship to early-stage companies. JLABS is the closest functional analog to adMare's Innovation Centre model, differing mainly in pharma sponsorship (J&J vs. AbbVie at adMare) and geographic spread (global vs. Canada-only).

TypeDirect peer
Description

Bayer's CoLaborator is a pharma-sponsored biotech incubator providing turnkey lab space and access to Bayer R&D expertise to early-stage companies, structurally similar to adMare's flagship AbbVie Biotech Innovators Award partnership and Innovation Centre residency model.

TypeDirect peer
Description

Toronto-based innovation hub hosting life sciences and other tech startups with shared infrastructure, talent programs, and ecosystem services. MaRS shares adMare's Canadian mandate and integrated infrastructure-plus-talent model, though it is broader across sectors (health, cleantech, fintech) rather than focused exclusively on life sciences.

TypeDirect peer
Description

CDL is a Canadian seed-stage accelerator with a dedicated Health stream, offering mentorship from experienced operators and investors to science-based startups. CDL complements adMare's company-creation engine with a venture-build curriculum, sharing Canadian roots and a focus on scaling science-driven companies.

TypeDirect peer
Description

BioEnterprise is a Canadian agri-food and life sciences commercialization accelerator offering advisory, capital access, and infrastructure to early-stage Canadian companies. It is comparable to adMare's role as a national commercialization platform, though narrower in life sciences sub-sectors.

TypeDirect peer
Description

IndieBio is a biotech-specific accelerator providing seed funding, lab space, and mentorship to biology-based startups. Its biology-only mandate and intensive company-building support parallel adMare's Accelerator and Innovation Centre offerings for therapeutic-biologics and adjacent companies.

TypeBroad incumbent
Description

Flagship Pioneering is a large US biotech venture creation firm that conceives, launches, and operates biotech companies (e.g., Moderna). It is comparable to adMare as a company-creation platform for breakthrough life sciences, but operates at much greater scale and with a for-profit, venture-backed model rather than a Canadian non-profit structure.

TypeDirect peer
Description

Atlas Venture is a Boston-based early-stage biotech-focused VC firm that builds and funds new therapeutic companies from inception. It parallels adMare's pre-seed/seed creation model for therapeutic biotech, though it operates as a traditional VC rather than providing lab infrastructure.

TypeBroad incumbent
Description

ARCH is a US venture firm that partners with universities and research institutions to found biotech companies, similar to adMare's company-creation model drawing on Canadian academic science. ARCH operates at significantly larger fund scale and with a US/global mandate.

10Velocity (Cambridge, UK)
TypeRegional player
Description

Velocity is a University of Cambridge-affiliated biotech incubator offering lab space, mentorship, and seed funding to UK life sciences startups. It is comparable to adMare's Innovation Centre+Accelerator model but serves a UK/European ecosystem rather than Canada.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment16 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

adMare Bio Innovations

Life Sciences Company Creation & Biotech Venture Developmentadmarebio.com

adMare BioInnovations is a Canadian mission-driven life sciences platform that provides early-stage capital, scientific and commercial expertise, turnkey lab facilities, and talent development to build and scale Canadian biotech companies. To date, it has helped create 39 companies with $5.8 billion in combined value.

What adMare Bio Innovations does

adMare BioInnovations is a Canadian life sciences company creation engine formed in 2019 from the merger of CDRD (Centre for Drug Research and Development) and Neomed Institute. The organization is structured as a mission-driven, non-profit platform that provides early-stage capital, scientific and commercial drug development expertise, intellectual property support, and turnkey laboratory and office infrastructure to help build and scale globally competitive Canadian life sciences companies. It serves three primary constituencies: early-stage life sciences companies (its core customer), life sciences professionals across Canada (community), and mid-career executives (leadership development). The organization operates over 200,000 square feet of turnkey facilities across three locations: the Vancouver Innovation Centre (including the newly opened M4 Centre in April 2026), the Montreal Innovation Centre, and a Toronto office at the MaRS Centre. The business model is not traditional commercial revenue generation; adMare is funded through government grants, service and facility income, and reinvested returns from portfolio company exits. Its product and service platform spans three pillars: Company Building (pre-seed investment, scientific and commercial R&D, IP and business development support), Ecosystems (innovation centre facilities, the AbbVie Biotech Innovators Award, and the adMare Community digital platform hosted on Hivebrite with 2,000+ members), and Talent (the adMare Executive Institute, adMare Academy's BIS Program, and experiential learning). The adMare Institute operates as a policy research arm producing white papers on Canadian life sciences.

adMare has helped create 39 companies that have collectively attracted $2.5 billion in risk capital and achieved a combined value of $5.8 billion, while generating more than $130 million in cash returns that are reinvested into the Canadian ecosystem. Recent portfolio company activity includes the launch of 26therapeutics (March 2026, dry eye disease), seed funding of Ocythera (January 2026, rare bone disease), Series B participation in Kainova Thérapeutiques ($32M CAD, February 2026, immuno-oncology), and the naming of RIME Therapeutics as the April 2026 AbbVie Biotech Innovators Award recipient. The adMare Academy has trained 800+ alumni (91% employed in the life sciences industry) and the Executive Institute has developed nearly 150 executives from over 100 Canadian life sciences organizations. Federal government support has been a material funding source, with grants from Innovation, Science and Economic Development Canada ($5M, December 2023) and Pacific Economic Development Canada ($4.2M, February 2025). In March-April 2026, founding President and CEO Gordon McCauley transitioned to Vice-Chair, with nine-year adMare executive Matthew J. Carlyle appointed President, CEO, and Director; Frédéric Lemaître Auger was concurrently promoted to Executive Vice President, Investments.

adMare Bio Innovations firmographics

Firmographics
Name
adMare Bio Innovations
Legal name
adMare BioInnovations
Website
https://admarebio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
adMare BioInnovations is a Canadian mission-driven life sciences platform that provides early-stage capital, scientific and commercial expertise, turnkey lab facilities, and talent development to build and scale Canadian biotech companies. To date, it has helped create 39 companies with $5.8 billion in combined value.
Ownership category
akta.pro rank

adMare Bio Innovations industry classification

Industry
Product category
Life Sciences Company Creation & Biotech Venture Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)

Keywords

  • Biotech company creation
  • Life sciences venture building
  • Pharmaceutical R&D infrastructure
  • Biotech talent development
  • Drug development services

Where adMare Bio Innovations is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices3 records

Markets served

adMare Bio Innovations business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Portfolio Returns and Reinvestment: adMare generates returns through its portfolio company exits (IPOs, M&A) and reinvests those returns back into the Canadian life sciences industry. The organization has generated more than $130 million in cash returns, which are plowed back into building new companies and supporting the ecosystem.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

adMare Bio Innovations product offering

Product offering

Core offering

adMare BioInnovations is a Canadian life sciences company creation engine that identifies breakthrough scientific discoveries and builds globally competitive biotech companies. It provides early-stage capital, scientific and commercial drug development expertise, turnkey laboratory and office infrastructure at Innovation Centres in Vancouver, Montreal, and Toronto, and industry-ready talent development programs, reinvesting returns from portfolio exits back into the Canadian life sciences ecosystem.

Product overview

adMare BioInnovations is Canada's life sciences company creation engine, offering a multi-component platform built around three pillars: (1) Company Building — providing early-stage capital, scientific expertise, commercial R&D, IP and business development support to create and scale globally competitive life sciences companies; (2) Ecosystems — operating turnkey lab and office facilities through Innovation Centres in Vancouver, Montreal, and Toronto (totaling more than 200,000 square feet), running the AbbVie Biotech Innovators Award competition, and maintaining the adMare Community digital networking platform; and (3) Talent — delivering the adMare Executive Institute (leadership development), BIS Program, and Experiential Learning programs. The adMare Institute provides policy research and white papers. adMare's portfolio includes 39 companies created to date, with a combined value of $5.8 billion.

Differentiator

Problem solved

Functional benefit

Brands

  • adMare Executive Institute: Canada's premier leadership development program for experienced mid-career executives and emerging C-suite leaders in the life sciences sector.
  • adMare Academy
  • adMare Innovation Centre
  • adMare Institute
  • adMare Community
  • AbbVie Biotech Innovators Award

Products and services

  • adMare Innovation Centre – Vancouver Turnkey laboratory and office facilities at 2405 Wesbrook Mall, Vancouver, British Columbia, providing workspace for emerging life sciences companies.
  • adMare Innovation Centre – Montreal Turnkey laboratory and office facilities at 7171 Frederick-Banting, Montréal, Québec, offering shared equipment and services for early-stage biotech companies.
  • adMare Executive Institute Canada's premier leadership development program for experienced mid-career executives and emerging C-suite leaders in the life sciences sector, combining in-person workshops, virtual peer sessions, executive coaching, and real-world leadership challenges. Has trained nearly 150 participants from more than 100 organizations across Canada.
  • AbbVie Biotech Innovators Award A national competition jointly run by AbbVie and adMare providing the winning Quebec biotech with one year of free laboratory and office space at the adMare Innovation Centre in Montreal, shared equipment access, and mentorship from AbbVie's scientific and business leaders.
  • adMare Accelerator An accelerator program for early-stage life sciences ventures providing hands-on company building support, capital, and access to infrastructure.
  • adMare Academy (BIS Program and Experiential Learning) Industry-ready talent development programs including the Business Innovation Studies (BIS) Program and experiential learning offerings that prepare individuals for careers in the Canadian life sciences industry. The Academy has trained more than 800 alumni, with 91% employed in the life sciences industry.
  • adMare Community A digital ecosystem bringing together over 2,000 life sciences professionals from students to CEOs across Canada, hosted on the Hivebrite platform, enabling networking, collaboration, and knowledge sharing.
  • Early-Stage Capital & Company Creation Pre-seed and early-stage investment capital provided to life sciences companies, with adMare co-investing alongside other investors to build globally competitive Canadian companies. To date, adMare has helped create 39 companies that have attracted $2.5 billion in risk capital.
  • adMare Institute A policy research institute dedicated to advancing public policy issues in life sciences in Canada, producing white papers on capital flows, anchor companies, and ecosystem development.
  • 26therapeutics Inc. Montreal-based life sciences company developing first-in-class topical small-molecule therapy for dry eye disease targeting meibomian gland dysfunction through CYP26B1 inhibition, created via adMare's company creation model.

Quantifiable outcome

  • 39 companies created that have attracted $2.5 billion in risk capital and achieved $5.8 billion combined value
  • +4 more outcomes

Companies that use adMare Bio Innovations

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles4 records

adMare Bio Innovations technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

adMare Bio Innovations partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core, minor and flagship.

  • VoxCell BioInnovationcoreStrategic or Co-development Partner · 13 May 2026Research partnership to validate the scientific and commercial potential of a novel antibody-based immune-modulating therapy using VoxCell's human-relevant vascularized cancer tissue models. Collaboration applies perfusable, immune-competent 3D bioprinted cancer tissue models to preclinical evaluation of next-generation oncology biologics.
  • Life Sciences BCminorStrategic or Co-development Partner · 17 April 2026Partnership with Life Sciences BC for ecosystem development. Life Sciences BC executives attended the ribbon-cutting ceremony for new lab facilities at adMare's Vancouver innovation centre.
  • AbbVieflagshipStrategic or Co-development Partner · 24 November 2025AbbVie and adMare jointly run the AbbVie Biotech Innovators Award program to support early-stage biotechnology companies in Quebec. The award provides lab/office space at the adMare Innovation Centre in Montreal, shared equipment access, and mentorship from AbbVie's scientific and business leaders. First awarded to RIME Therapeutics in April 2026.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

adMare Bio Innovations competitors and assessment

Company assessment

Direct peers

  • Johnson & Johnson Innovation – JLABS: JLABS operates a global network of no-strings-attached biotech incubators offering turnkey lab space, equipment, and mentorship to early-stage companies. JLABS is the closest functional analog to adMare's Innovation Centre model, differing mainly in pharma sponsorship (J&J vs. AbbVie at adMare) and geographic spread (global vs. Canada-only).
  • Bayer CoLaborator: Bayer's CoLaborator is a pharma-sponsored biotech incubator providing turnkey lab space and access to Bayer R&D expertise to early-stage companies, structurally similar to adMare's flagship AbbVie Biotech Innovators Award partnership and Innovation Centre residency model.
  • MaRS Discovery District: Toronto-based innovation hub hosting life sciences and other tech startups with shared infrastructure, talent programs, and ecosystem services. MaRS shares adMare's Canadian mandate and integrated infrastructure-plus-talent model, though it is broader across sectors (health, cleantech, fintech) rather than focused exclusively on life sciences.
  • Creative Destruction Lab (CDL): CDL is a Canadian seed-stage accelerator with a dedicated Health stream, offering mentorship from experienced operators and investors to science-based startups. CDL complements adMare's company-creation engine with a venture-build curriculum, sharing Canadian roots and a focus on scaling science-driven companies.
  • BioEnterprise: BioEnterprise is a Canadian agri-food and life sciences commercialization accelerator offering advisory, capital access, and infrastructure to early-stage Canadian companies. It is comparable to adMare's role as a national commercialization platform, though narrower in life sciences sub-sectors.
  • IndieBio: IndieBio is a biotech-specific accelerator providing seed funding, lab space, and mentorship to biology-based startups. Its biology-only mandate and intensive company-building support parallel adMare's Accelerator and Innovation Centre offerings for therapeutic-biologics and adjacent companies.
  • Atlas Venture: Atlas Venture is a Boston-based early-stage biotech-focused VC firm that builds and funds new therapeutic companies from inception. It parallels adMare's pre-seed/seed creation model for therapeutic biotech, though it operates as a traditional VC rather than providing lab infrastructure.

Broad incumbents

  • Flagship Pioneering: Flagship Pioneering is a large US biotech venture creation firm that conceives, launches, and operates biotech companies (e.g., Moderna). It is comparable to adMare as a company-creation platform for breakthrough life sciences, but operates at much greater scale and with a for-profit, venture-backed model rather than a Canadian non-profit structure.
  • ARCH Venture Partners: ARCH is a US venture firm that partners with universities and research institutions to found biotech companies, similar to adMare's company-creation model drawing on Canadian academic science. ARCH operates at significantly larger fund scale and with a US/global mandate.

Regional players

  • Velocity (Cambridge, UK): Velocity is a University of Cambridge-affiliated biotech incubator offering lab space, mentorship, and seed funding to UK life sciences startups. It is comparable to adMare's Innovation Centre+Accelerator model but serves a UK/European ecosystem rather than Canada.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

adMare Bio Innovations social profiles

Digital presence

adMare Bio Innovations financial estimates

Financial estimate

Revenue estimate

Valuation estimate

adMare Bio Innovations leadership team

Management profile

Number of profiles

Profiles9 records

adMare Bio Innovations funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

adMare Bio Innovations M&A and investment

M&A and investment

M&A1 record

Investments16 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about adMare Bio Innovations

What does adMare Bio Innovations do?

adMare BioInnovations is a Canadian life sciences company creation engine that identifies breakthrough scientific discoveries and builds globally competitive biotech companies. It provides early-stage capital, scientific and commercial drug development expertise, turnkey laboratory and office infrastructure at Innovation Centres in Vancouver, Montreal, and Toronto, and industry-ready talent development programs, reinvesting returns from portfolio exits back into the Canadian life sciences ecosystem.

Is adMare Bio Innovations a public or private company?

adMare Bio Innovations is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was adMare Bio Innovations founded?

adMare Bio Innovations was founded in 2019. It employs 51 to 100 people.

Where is adMare Bio Innovations based?

adMare Bio Innovations is headquartered in Vancouver, Canada, in the North America region.

How does adMare Bio Innovations make money?

One revenue line is on record: portfolio Returns and Reinvestment.

Who are adMare Bio Innovations's main competitors?

Direct peers on record are Johnson & Johnson Innovation – JLABS, Bayer CoLaborator, MaRS Discovery District, Creative Destruction Lab (CDL), BioEnterprise, IndieBio and Atlas Venture. Broad incumbents are Flagship Pioneering and ARCH Venture Partners. Velocity (Cambridge, UK) is listed as a regional player.

Does adMare Bio Innovations have an API?

No public API is recorded for adMare Bio Innovations.

What industry is adMare Bio Innovations in?

adMare Bio Innovations's product category is Life Sciences Company Creation & Biotech Venture Development. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Financial PostAbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in QuebecAbbVie and adMare BioInnovations named RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award in Quebec, providing one year of laboratory and office space at the adMare Innovation Centre in Montreal along with mentorship from AbbVie\u2019s scientific and business leaders. Founded in 2025, RIME Therapeutics is a Montreal-based startup developing a peptide-based drug discovery platform targeting protein-protein interactions for inflammation and immunology therapies. The award aims to support early-stage biotechnology companies with potential for transformational therapies aligned with AbbVie\u2019s therapeutic focus areas.GlobeNewswireAbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in QuebecAbbVie and adMare BioInnovations jointly recognized Montreal-based startup RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award in Quebec on April 30, 2026. The award provides RIME Therapeutics with one year of laboratory and office space at the adMare Innovation Centre in Montreal, along with access to shared equipment and mentorship from AbbVie's scientific and business leaders. RIME Therapeutics, founded in 2025, is developing a peptide-based drug discovery platform focused on inflammation and immunology therapies.GlobeNewswireAbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in QuebecAbbVie and adMare BioInnovations jointly named RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award, a prize designed to support innovation in Quebec's life sciences sector. The award provides the Montreal-based startup with one year of laboratory and office space at the adMare Innovation Centre in Montreal, along with access to shared equipment and mentorship from AbbVie's scientific and business leaders. Founded in 2025, RIME Therapeutics is developing a peptide-based drug discovery platform focused on inflammation and immunology therapies.Quiver QuantitativeAbbVie and adMare BioInnovations Award RIME Therapeutics to Advance Biotech Innovation in QuebecAbbVie, in partnership with adMare BioInnovations, has awarded the AbbVie Biotech Innovators Award to Montreal-based start-up RIME Therapeutics, which specializes in peptide-based drug discovery for inflammation and immunology. The award provides RIME Therapeutics with one year of laboratory and office space at the adMare Innovation Centre, including shared equipment access and mentorship from AbbVie's leadership. Both organizations emphasize supporting early-stage biotech innovation in Canada to foster growth in the life sciences sector.Business in VancouverNew lab facilities add to Vancouver’s life sciences infrastructureA ribbon-cutting ceremony for new life sciences laboratory facilities was held at the adMare innovation centre in Vancouver's Mount Pleasant neighbourhood on Friday, April 17. The event featured attendance by executives from adMare BioInnovations and Life Sciences BC, along with B.C. Minister of Jobs and Economic Growth Ravi Kahlon. The new facilities are intended to provide workspace for emerging life sciences companies.GlobeNewswireAbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in QuebecAbbVie and adMare BioInnovations launched the AbbVie Biotech Innovators Award to support early-stage Quebec biotech startups. The winner receives a year of lab and office space at adMare's Montreal Innovation Centre plus executive mentorship. Applications are open until February 20, 2026.